



# Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab

Tobin J Cammett<sup>1</sup> · Katherine Garlo<sup>1</sup> · Ellen E Millman<sup>1</sup> · Kara Rice<sup>1</sup> · Catherine M Toste<sup>1</sup> · Susan J. Faas<sup>1</sup>

Accepted: 7 February 2023 / Published online: 4 March 2023  
© The Author(s) 2023

## Correction to:

**Molecular Diagnosis & Therapy (2023) 27:61–74**  
<https://doi.org/10.1007/s40291-022-00620-3>

In the original publication of the article, there are Corrections in the author affiliations. The listing of the author names and affiliations, which previously read:

Tobin J Cammett<sup>1</sup>, Katherine Garlo<sup>2</sup>, Ellen E Millman<sup>2</sup>, Kara Rice<sup>2</sup>, Catherine M Toste<sup>2</sup>, Susan J Faas<sup>2</sup>

- <sup>1</sup>Alexion, AstraZeneca Rare Disease, Boston, MA, USA. [tobin.cammett@alexion.com](mailto:tobin.cammett@alexion.com).
- <sup>2</sup>Alexion, AstraZeneca Rare Disease, Boston, MA, USA.

should read:

Tobin J Cammett<sup>1</sup>, Katherine Garlo<sup>1</sup>, Ellen E Millman<sup>1</sup>, Kara Rice<sup>1</sup>, Catherine M Toste<sup>1</sup>, Susan J Faas<sup>1</sup>

- <sup>1</sup>Alexion, AstraZeneca Rare Disease, Boston, MA, USA. [tobin.cammett@alexion.com](mailto:tobin.cammett@alexion.com).

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

---

Susan J. Faas was employed by Alexion, AstraZeneca Rare Disease, at the time of this study.

---

The original article can be found online at <https://doi.org/10.1007/s40291-022-00620-3>.

---

✉ Tobin J Cammett  
[tobin.cammett@alexion.com](mailto:tobin.cammett@alexion.com)

<sup>1</sup> Alexion, AstraZeneca Rare Disease, Boston, MA, USA